DMARDS and infections in rheumatoid arthritis

Autoimmunity Reviews

Volumn 8, Issue 2, 2008, Pages 139-143

  Caporali, Roberto ^a   Caprioli, Marta ^a   Bobbio Pallavicini, Francesca ^a   Montecucco, Carlomaurizio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

DMARDs; Infection; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISOLONE; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

BACTERIAL ARTHRITIS; CELLULAR IMMUNITY; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GOLD THERAPY; HOSPITALIZATION; HUMAN; INFECTION; INFECTION RISK; LOWER RESPIRATORY TRACT INFECTION; OPPORTUNISTIC INFECTION; PNEUMONIA; REVIEW; RHEUMATOID ARTHRITIS; RISK REDUCTION; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; INFECTION; ISOXAZOLES; METHOTREXATE; RISK FACTORS;

EID: 56349118190     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.05.001     Document Type: Review

References (40)

1. Baum J. Infection in rheumatoid arthritis. Arthritis Rheum 14 (1971) 135-137
2. Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., and Gabriel S.E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46 (2002) 2287-2293
3. Reilly P.A., Cosh J.A., Maddison P.J., Rasker J.J., and Silman A.J. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 49 (1990) 363-369
4. Bernatsky S., Hudson M., and Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 46 (2007) 1157-1160
5. Wolfe F., Caplan L., and Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum 54 (2006) 628-634
6. Mikuls T.R. Co-morbidity in rheumatoid arthritis. Best Pract Res Clin Rheumatol 17 (2003) 729-752
7. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 66 10 (2007) 1339-1344
8. Winthrop K.L. Serious infections with antirheumatic therapy: are biologicals worse?. Ann Rheum Dis 65 Suppl 3 (2006) iii54-iii57
9. Jick S.S., Lieberman E.S., Rahman M.U., and Choi H.K. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 55 (2006) 19-26
10. Nandi P., Kingsley G.H., and Scott D.L. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis. Curr Opin Rheumatol 20 (2008) 251-256
11. Sokka T., and Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. J Rheumatol 29 (2002) 2521-2524
12. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Ludviksson B.R., and Valdimarsson H. The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114 (2005) 154-163
13. van der Veen M.J., van der Heide A., Kruize A.A., and Bijlsma J.W. Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis 53 (1994) 224-228
14. Boerbooms A.M., Kerstens P.J., van Loenhout J.W., Mulder J., and van de Putte L.B. Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum 24 (1995) 411-421
15. Atzeni F., Bendtzen K., Bobbio-Pallavicini F., Conti F., Cutolo M., Montecucco C., et al. Infections and treatment of patients with rheumatic diseases. Clin.Exp.Rheumatol 26 1 (2008) S67-S73
16. Schnabel A., Herlyn K., Burchardi C., Reinhold-Keller E., and Gross W.L. Long-term tolerability of methotrexate at doses exceeding 15 mg per week in rheumatoid arthritis. Rheumatol Int 15 (1996) 195-200
17. Aletaha D., Kapral T., and Smolen J.S. Toxicity profiles of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. Ann Rheum Dis 62 (2003) 482-486
18. van der Heijde D.M., Klareskog L., Landewe R., Bruyn G.A., Cantagrel A., Durez P., et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 56 (2007) 3928-3939
19. Smitten A.L., Choi H.K., Hochberg M.C., Suissa S., Simon T.A., Testa M.A., and Chan K.A. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 35 (2008) 387-393
20. Pieringer H., Stuby U., and Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?. Semin Arthritis Rheum 36 (2007) 278-286
21. LeMense G.P., and Sahn S.A. Opportunistic infection during treatment with low dose methotrexate. Am J Respir Crit Care Med 150 (1994) 258-260
22. Antonelli M.A., Moreland L.W., and Brick J.E. Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 90 (1991) 295-298
23. Smitten A.L., Choi H.K., Hochberg M.C., Suissa S., Simon T.A., Testa M.A., and Chan K.A. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 57 (2007) 1431-1438
24. Brassard P., Kezouh A., and Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43 (2006) 717-722
25. Cohen S., Cannon G.W., Schiff M., Weaver A., Fox R., Olsen N., et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of leflunomide in the treatment of rheumatoid arthritis trial investigator group. Arthritis Rheum 44 (2001) 1984-1992
26. Kalden J.R., Schattenkirchner M., Sorensen H., Emery P., Deighton C., Rozman B., and Breedveld F. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 48 (2003) 1513-1520
27. Hocevar A., Rozman B., Praprotnik S., Lestan B., Erzen D., Petric V., and Tomsic M. Leflunomide-associated tuberculosis?. Rheumatology (Oxford) 45 (2006) 228-229
28. Jenks K.A., Stamp L.K., O'Donnell J.L., Savage R.L., and Chapman P.T. Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol 34 (2007) 2201-2203
29. Gran J.T., and Myklebust G. Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids. Scand J Rheumatol 22 (1993) 229-232
30. Edwards C.J., Cooper C., Fisher D., Field M., van Staa T.P., and Arden N.K. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. Arthritis Rheum 57 (2007) 1151-1157
31. Munster T., Gibbs J.P., Shen D., Baethge B.A., Botstein G.R., Caldwell J., et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46 (2002) 1460-1469
32. Bendix G., and Bjelle A. A 10 year follow up of parenteral gold therapy in patients with rheumatoid arthritis. Ann Rheum Dis 55 (1996) 169-176
33. Marra C.A., Esdaile J.M., Guh D., Fisher J.H., Chalmers A., and Anis A.H. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum 45 (2001) 240-245
34. Gerards A.H., Landewe R.B., Prins A.P., Bruyn G.A., Goei The H.S., Laan R.F., and Dijkmans B.A. Cyclosporin A monotherapy versus cyclosporin A and methotrexate combination therapy in patients with early rheumatoid arthritis: a double blind randomised placebo controlled trial. Ann Rheum Dis 62 (2003) 291-296
35. O'Dell J.R., Leff R., Paulsen G., Haire C., Mallek J., Eckhoff P.J., et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46 (2002) 1164-1170
36. Lehman A.J., Esdaile J.M., Klinkhoff A.V., Grant E., Fitzgerald A., and Canvin J. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis Rheum 52 (2005) 1360-1370
37. Boers M., Verhoeven A.C., Markusse H.M., van de Laar M.A., Westhovens R., van Denderen J.C., et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350 (1997) 309-318
38. Capell H.A., Madhok R., Porter D.R., Munro R.A., McInnes I.B., Hunter J.A., et al. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 66 (2007) 235-241
39. Ferraccioli G.F., Gremese E., Tomietto P., Favret G., Damato R., and Di P.E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 41 (2002) 892-898
40. Kremer J.M., Genovese M.C., Cannon G.W., Caldwell J.R., Cush J.J., Furst D.E., et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 137 (2002) 726-733